What changed from existing technology?
This study introduces a new method to detect bladder cancer and predict treatment response by analyzing RNA in urine, which is less invasive than traditional methods.
This is the first study to use urine cell-free RNA for both detecting bladder cancer and predicting treatment response, offering a noninvasive alternative to current methods.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
fRNA profiling, and apply it to 683 urine samples from patients with cancer and controls. Urine cfRNA contained transcripts from genitourinary tissues and, in
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This method could be used for noninvasive bladder cancer screening and monitoring treatment response, potentially improving early detection and personalized treatment strategies.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.